JP7170368B2 - 疾患リスク評価方法、疾患リスク評価装置、及び疾患リスク評価プログラム - Google Patents

疾患リスク評価方法、疾患リスク評価装置、及び疾患リスク評価プログラム Download PDF

Info

Publication number
JP7170368B2
JP7170368B2 JP2022539503A JP2022539503A JP7170368B2 JP 7170368 B2 JP7170368 B2 JP 7170368B2 JP 2022539503 A JP2022539503 A JP 2022539503A JP 2022539503 A JP2022539503 A JP 2022539503A JP 7170368 B2 JP7170368 B2 JP 7170368B2
Authority
JP
Japan
Prior art keywords
data
estimation model
nash
risk
physical findings
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022539503A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022025069A1 (https=
JPWO2022025069A5 (https=
Inventor
武 岡上
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
THINKMEDICAL INC.
Original Assignee
THINKMEDICAL INC.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by THINKMEDICAL INC. filed Critical THINKMEDICAL INC.
Publication of JPWO2022025069A1 publication Critical patent/JPWO2022025069A1/ja
Publication of JPWO2022025069A5 publication Critical patent/JPWO2022025069A5/ja
Application granted granted Critical
Publication of JP7170368B2 publication Critical patent/JP7170368B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/61—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving triglycerides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Databases & Information Systems (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Data Mining & Analysis (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2022539503A 2020-07-28 2021-07-27 疾患リスク評価方法、疾患リスク評価装置、及び疾患リスク評価プログラム Active JP7170368B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020127010 2020-07-28
JP2020127010 2020-07-28
PCT/JP2021/027776 WO2022025069A1 (ja) 2020-07-28 2021-07-27 疾患リスク評価方法、疾患リスク評価装置、及び疾患リスク評価プログラム

Publications (3)

Publication Number Publication Date
JPWO2022025069A1 JPWO2022025069A1 (https=) 2022-02-03
JPWO2022025069A5 JPWO2022025069A5 (https=) 2022-11-10
JP7170368B2 true JP7170368B2 (ja) 2022-11-14

Family

ID=80036648

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022539503A Active JP7170368B2 (ja) 2020-07-28 2021-07-27 疾患リスク評価方法、疾患リスク評価装置、及び疾患リスク評価プログラム

Country Status (3)

Country Link
US (1) US20230274840A1 (https=)
JP (1) JP7170368B2 (https=)
WO (1) WO2022025069A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102616840B1 (ko) 2023-02-17 2023-12-21 주식회사 바이오뉴트리온 비알코올성 지방간질환 위험성 자가 평가 방법
WO2024172240A1 (ko) * 2023-02-17 2024-08-22 주식회사 바이오뉴트리온 비알코올성 지방간질환 위험성 자가 평가 방법

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115116615A (zh) * 2022-07-11 2022-09-27 江苏亚寰软件股份有限公司 一种对非酒精性脂肪肝风险的分析预测方法及系统
WO2024097993A1 (en) * 2022-11-06 2024-05-10 Mayo Foundation For Medical Education And Research Machine learning-based risk stratification and management of non-alcoholic fatty liver disease
WO2025173349A1 (ja) * 2024-02-16 2025-08-21 Ｎｅｃソリューションイノベータ株式会社 疾患発症リスク予測装置、予測マーカセット、予測方法、プログラム、及び記録媒体

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012194170A (ja) 2011-03-02 2012-10-11 Nagasaki Univ ペプチドの検出方法
WO2015019976A1 (ja) 2013-08-05 2015-02-12 第一三共株式会社 肝障害のタイプの検査方法
WO2017043617A1 (ja) 2015-09-10 2017-03-16 エーディア株式会社 肝癌の検査方法
WO2019220833A1 (ja) 2018-05-18 2019-11-21 株式会社島津製作所 診断支援システムおよび診断支援装置
WO2020096043A1 (ja) 2018-11-09 2020-05-14 積水メディカル株式会社 ウィルス性肝癌の検出方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050096530A1 (en) * 2003-10-29 2005-05-05 Confirma, Inc. Apparatus and method for customized report viewer
US8275442B2 (en) * 2008-09-25 2012-09-25 Zeltiq Aesthetics, Inc. Treatment planning systems and methods for body contouring applications
WO2014028494A1 (en) * 2012-08-13 2014-02-20 The Regents Of The University Of California Detecting and treating liver damage
WO2015120064A1 (en) * 2014-02-04 2015-08-13 Cardioinsight Technologies, Inc. Integrated analysis of electrophysiological data
TW201643760A (zh) * 2015-04-10 2016-12-16 Social Welfare Organization Saiseikai Imp Gift Foundation Inc Saiseikai Suita Hospital 判別肝疾病之疾病狀態之方法
WO2018124831A1 (ko) * 2016-12-30 2018-07-05 서울대학교 산학협력단 대사이상 질환의 질병 위험도를 예측하는 장치 및 방법
WO2019191059A1 (en) * 2018-03-26 2019-10-03 The General Hospital Corporation Method for objective, noninvasive staging of diffuse liver disease from ultrasound shear-wave elastography
US10978176B2 (en) * 2018-06-29 2021-04-13 pulseData Inc. Machine learning systems and methods for predicting risk of renal function decline

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012194170A (ja) 2011-03-02 2012-10-11 Nagasaki Univ ペプチドの検出方法
WO2015019976A1 (ja) 2013-08-05 2015-02-12 第一三共株式会社 肝障害のタイプの検査方法
WO2017043617A1 (ja) 2015-09-10 2017-03-16 エーディア株式会社 肝癌の検査方法
WO2019220833A1 (ja) 2018-05-18 2019-11-21 株式会社島津製作所 診断支援システムおよび診断支援装置
WO2020096043A1 (ja) 2018-11-09 2020-05-14 積水メディカル株式会社 ウィルス性肝癌の検出方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ATABAKI-PASDAR, N. et al.，Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and vali，PLOS MEDLINE，2020年06月19日，Vol.17, No.6，pp.1-27
FIALOKE, S. et al.，Application of Machine Learning Methods to Predict Non-Alcoholic Steatohepatitis (NASH) in Non-Alcoh，AMIA Annual Symposium Proceedings Archive，2018年12月05日，pp.430-439
POYNARD, T. et al.，The diagnostic value of biomarkers (Steato Test) for the prediction of liver steatosis，Comparative Hepatology，2005年12月23日，Vol.4, Article number: 10，pp.1-14

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102616840B1 (ko) 2023-02-17 2023-12-21 주식회사 바이오뉴트리온 비알코올성 지방간질환 위험성 자가 평가 방법
WO2024172240A1 (ko) * 2023-02-17 2024-08-22 주식회사 바이오뉴트리온 비알코올성 지방간질환 위험성 자가 평가 방법

Also Published As

Publication number Publication date
US20230274840A1 (en) 2023-08-31
JPWO2022025069A1 (https=) 2022-02-03
WO2022025069A1 (ja) 2022-02-03

Similar Documents

Publication Publication Date Title
JP7170368B2 (ja) 疾患リスク評価方法、疾患リスク評価装置、及び疾患リスク評価プログラム
US20250306025A1 (en) Method of prognosis and follow up of primary liver cancer
Anaizi et al. Diagnosing chronic pancreatitis
Tatham et al. Strategies for improving early detection of glaucoma: the combined structure–function index
CN112805789A (zh) 诊断肝脂肪变性的方法
Santoro et al. Early and accurate diagnosis of steatotic liver by artificial intelligence (AI)-supported ultrasonography
CN104094264B (zh) 用于诊断晚期肝纤维化的装置
Silva et al. Prevalence of sarcopenia in older women with pelvic floor dysfunction
CA3036962A1 (en) Method of diagnosis of non-alcoholic fatty liver diseases
EP2684513A1 (en) Method for providing reliable non-invasive diagnostic tests
Khani et al. Comparison of hepatic steatosis index as noninvasive diagnostic tool and liver ultrasound for non-alcoholic steatosis in the adult population
Zhu et al. Automatic kidney stone identification: an adaptive feature-weighted LSTM model based on urine and blood routine analysis
Onishi et al. Artificial intelligence for body composition assessment focusing on sarcopenia
Balakrishnan et al. MASLD Risk Score (MRS) and Random Forest model (RF Model): Novel tools for screening and severity assessment of MASLD
CN118568548B (zh) 基于Reg III蛋白的溃疡性结肠炎疾病活动度预测方法及系统
JP2018512208A (ja) 肝臓の病変を定量化または決定するためのｍｒ（磁気共鳴）画像のコンピュータ化された光学的分析方法
Ha et al. Multi-classification of osteoporosis grading stages using abdominal computed tomography with clinical variables: application of deep learning with a convolutional neural network
Bangaru et al. Predictive algorithm for hepatic steatosis detection using elastography data in the veterans affairs electronic health records
Musleh et al. A machine learning based study to assess bone health in a diabetic cohort
Yin et al. Prospective multicenter study on the reproducibility of ultrasound-derived fat fraction in assessing hepatic steatosis
Chee et al. The past, present, and future of noninvasive test in chronic liver diseases
Kim et al. Different trends of teeth marks according to qi blood yin yang deficiency pattern in patients with chronic fatigue
EP4481388A1 (en) Method of diagnosis of liver steatosis
EP4481389A1 (en) Method of diagnosis of non-alcoholic steatotic hepatitis
Mohammadi et al. Diagnostic value of serologic biomarkers for the detection of liver fibrosis in non-alcoholic fatty liver disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220803

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220803

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220803

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220927

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221004

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221025

R150 Certificate of patent or registration of utility model

Ref document number: 7170368

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250